Clinical trial NCT02654769: A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
Official title: Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Actinic Keratosis
Lead sponsor: Actavis Inc.
Sponsor class: INDUSTRY
First posted: 2016-01-13
Enrollment: 441
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.05% to Picato gel, 0.05% and to establish the superiority of the efficacy of these two products over the vehicle gel in the treatment of Actinic Keratosis (AK) on the trunk or extremities.

Detailed description: Picato® (ingenol mebutate) gel is the first and only ingenol mebutate product approved by the FDA in 2012 for the topical treatment of AK(s) on the face and scalp (0.015% formulation) and on the trunk and extremities (0.05% formulation). A generic ingenol mebutate gel, 0.05% has been developed for the topical treatment of clinically typical, visible, and discrete non-hyperkeratotic, non-hypertrophic AK lesions of the trunk or extremities.

Eligibility criteria: Inclusion Criteria:

* Subject was a male or non-pregnant female 18 years of age or older
* Subject provided written informed consent.
* Subject was willing and able to apply the test article as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
* Subject had a clinical diagnosis of AK at Baseline with at least four (4), but no more than eight (8), visible and discrete non-hyperkeratotic, non-hypertrophic AK lesions, each at least 4 mm in diameter, within a contiguous 25 cm2 treatment area ("the Treatment Area") on the trunk or extremities.
* Subject was in good general health and free of any disease state or physical condition that might have impaired evaluation of AK lesions or which, in the investigator's opinion, exposed the subject to an unacceptable risk by study participation.
* Females must have been post-menopausal , surgically sterile , or have used an effective method of birth control , with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion Criteria:

* Subject was pregnant, lactating, or was planning to become pregnant during the study.
* Subject was currently enrolled in an investigational drug or device study.
* Subject used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
* Subject had hyperkeratotic, hypertrophic, or large mat-like AKs (e.g., AK \>1 cm2 in size) within the contiguous 25 cm2 Treatment Area.
* Subject had more than eight (8) AKs, independent of size, within the contiguous 25 cm2 Treatment Area.
* Subject had the need or planned to be exposed to artificial tanning devices or excessive sunlight during the trial.
* Subject was immunosuppressed (e.g., HIV, systemic malignancy, graft host disease, etc.)
* Subject had experienced an unsuccessful outcome from previous ingenol mebutate therapy (an unsuccessful outcome was defined as after a reasonable therapeutic trial with no compliance issues and the topical drug did not work).
* Subject had a history of sensitivity to any of the ingredients in the test articles (see Section 9.4.2).
* Subject used topical creams, lotions, or gels of any kind within the selected Treatment Area within one (1) day prior to entry into the study.
* Subject used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid etc. \>5%), beta hydroxy acid (salicylic acid \>2%), urea \>5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.
* Subject had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.
* Subject used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within one (1) month prior to the Baseline Visit.
* Subject had dermatologic procedures or surgeries such as laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B (UVB) therapy, chemical peels, or dermabrasion on the selected Treatment area (trunk or extremities) within six (6) months prior to the Baseline Visit.
* Subject had lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected Treatment Area (trunk or extremities).
* Subject had any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the test article or required the use of interfering topical, systemic, or surgical therapy.
* Subject had any condition which, in the investigator's opinion, would have made it unsafe or precluded the subject's ability to fully participate in this research study.
* Subject was unable to communicate or cooperate with the investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.
* Subject was known to be noncompliant or was unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
* Subject had been previously enrolled in the same study.

Primary outcomes:
measure: Primary Efficacy Outcome Measure
timeFrame: 8 weeks
Secondary outcomes:
measure: The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Fremont
country: United States
facility: Center for Dermatology Clinical Research, Inc
state: California
city: San Diego
country: United States
facility: SD Sports Medicine & Family Health Center
state: California
city: Aventura
country: United States
facility: The Center for Clinical and Cosmetic Research
state: Florida
city: Miami Lakes
country: United States
facility: Savin Medical Group Research Center
state: Florida
city: North Miami Beach
country: United States
facility: Tory P. Sullivan, M.D., P.A.
state: Florida
city: Tampa
country: United States
facility: Moore Clinical Research, Inc.
state: Florida
city: Boise
country: United States
facility: Northwest Clinical Trials, Inc.
state: Idaho
city: Arlington Heights
country: United States
facility: Altman Dermatology Associates
state: Illinois
city: Champaign
country: United States
facility: Christie Clinic, LLC
state: Illinois
city: Carmel
country: United States
facility: Shideler Clinical Research Center
state: Indiana
city: Indianapolis
country: United States
facility: Dawes Fretzin Clinical Research Group, LLC
state: Indiana
city: Plainfield
country: United States
facility: The Indiana Clinical Trials Center
state: Indiana
city: Henderson
country: United States
facility: Bettencourt Skin Center
state: Nevada
city: New York
country: United States
facility: Union Square Dermatology
state: New York
city: High Point
country: United States
facility: Dermatology Consulting Services
state: North Carolina
city: Winston-Salem
country: United States
facility: PMG Research of Winston-Salem, LLC
state: North Carolina
city: Warwick
country: United States
facility: Omega Medical Research, 400 Bald Hill Road, Warwick, RI 02886
state: Rhode Island
city: Greenville
country: United States
facility: Greenville Dermatology, LLC
state: South Carolina
city: Knoxville
country: United States
facility: Dermatology Associates of Knoxville, PC
state: Tennessee
city: Austin
country: United States
facility: DermResearch, Inc.Austin
state: Texas
city: Houston
country: United States
facility: The Center for Skin Research
state: Texas
city: Norfolk
country: United States
facility: Virginia Clinical Research
state: Virginia
Study officials:
affiliation: Actavis Inc.
name: Oleg Khatsenko, Ph.D
role: STUDY_DIRECTOR
References: